Health-Holland

The Netherlands maintains strong positions in biopharmaceuticals, human and veterinary vaccines, and regenerative medicine. In 2018, 197 biotech medicines were being developed in the Netherlands, the majority of which (97) were at pre-clinical trial stage, and 11 of which were already in Phase III. Most of the biotech products available on the market are for the treatment of cancer, infectious and parasitic diseases, and diseases of the nervous system. Medicine development Source: The Dutch Life Sciences Trend Analysis 2018 Source: The Dutch Life Sciences Trend Analysis 2018 197 Biotech medicines in development Biotech products - breakdown by therapeutic area 97 Preclinical Other Pregnancy, childbirth and the puerperium Diseases of the ear Mental and behavioural disorders Conditions originating in the perinatal period Skin and subcutaneous tissue Diseases of the eye Infectious and parasitic diseases Cardiovascular Respiratory Neoplasms / cancer / oncology Genitourinary system Digestive system Musculoskeletal system and connective tissue Diseases of the blood and blood-forming organs; immune disorders Symptoms, signs and abnormal clinical and laboratory findings Endocrine, nutritional and metabolic diseases Injury, poisoning and other consequences of external causes 42 Phase I 47 Phase II 11 Phase III 0 25 50 75 100 125 Diseases of the nervous systems 24